Akebia Therapeutics, Inc. Operating Income Loss

• Akebia Therapeutics, Inc. showed an increase of +146.6% in Operating Income Loss from 2024 to 2025.
• This data is from Akebia Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
• XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 14 years of available data (2012 to 2025), Akebia Therapeutics, Inc.'s Operating Income Loss has grown by 375.7%.
• Historical annual values: Fiscal year 2025: $23.50 million | Fiscal year 2024: -$50.47 million | Fiscal year 2023: -$46.26 million | Fiscal year 2022: -$80.78 million | Fiscal year 2021: -$265.32 million | Fiscal year 2020: -$376.44 million | Fiscal year 2019: -$286.29 million | Fiscal year 2018: -$178.16 million | Fiscal year 2017: -$76.67 million | Fiscal year 2016: -$136.46 million | Fiscal year 2015: -$61.51 million | Fiscal year 2014: -$37.94 million | Fiscal year 2013: -$15.93 million | Fiscal year 2012: -$8.52 million.
• Data sourced from SEC EDGAR public filings as of June 21, 2026.

Last verified: June 21, 2026